

# Haralabos P Kalofonos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3969382/publications.pdf>

Version: 2024-02-01

281  
papers

10,392  
citations

38660

50  
h-index

48187

88  
g-index

283  
all docs

283  
docs citations

283  
times ranked

13127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
2	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
3	Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. <i>Blood</i> , 2008, 112, 1593-1599.	0.6	362
4	A review on oxaliplatin-induced peripheral nerve damage. <i>Cancer Treatment Reviews</i> , 2008, 34, 368-377.	3.4	275
5	Adjuvant MAGE-A3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results. <i>Journal of Clinical Oncology</i> , 2013, 31, 2396-2403.	0.8	275
6	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013, 24, 454-462.	0.6	232
7	Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. <i>Cancer Management and Research</i> , 2014, 6, 135.	0.9	222
8	Peripheral nerve damage associated with administration of taxanes in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 218-228.	2.0	211
9	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
10	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 447-456.	1.1	169
11	Either Called "Chemobrain" or "Chemofog," the Long-Term Chemotherapy-Induced Cognitive Decline in Cancer Survivors Is Real. <i>Journal of Pain and Symptom Management</i> , 2011, 41, 126-139.	0.6	155
12	Financial crisis and austerity measures in Greece: Their impact on health promotion policies and public health care. <i>Health Policy</i> , 2013, 113, 8-12.	1.4	154
13	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	0.6	136
14	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2005, 97, 436-441.	0.6	133
15	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i> , 2009, 115, 1544-1554.	2.0	127
16	A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. <i>Supportive Care in Cancer</i> , 2006, 14, 1134-1140.	1.0	121
17	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	0.9	116
18	Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 237-244.	0.6	113

#	ARTICLE	IF	CITATIONS
19	Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Annals of Oncology</i> , 2001, 12, 1231-1238.	0.6	111
20	Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. <i>Cancer</i> , 2004, 101, 404-411.	2.0	107
21	Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 939-944.	0.8	107
22	Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 237-244.	1.1	101
23	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 1762-1771.	0.6	95
24	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 178-189.	2.1	92
25	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86
26	Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. <i>Acta Oncologica</i> , 2007, 46, 1131-1137.	0.8	80
27	Characterization and Biological Evaluation of Propolis from Poland. <i>Molecules</i> , 2017, 22, 1159.	1.7	80
28	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
29	Intratumoral Doxorubicin in Patients With Malignant Brain Gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 60-64.	0.6	76
30	A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 87-99.	1.1	74
31	The upgraded role of HER3 and HER4 receptors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 73-78.	2.0	74
32	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , 2014, 88, 1669-1679.	1.9	73
33	Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. <i>Supportive Care in Cancer</i> , 2006, 14, 223-229.	1.0	71
34	Expression of the ribonucleases Droscha, Dicer, and Ago2 in colorectal carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 431-440.	1.4	69
35	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3116-3122.	0.6	69
36	Information needs and awareness of diagnosis in patients with cancer receiving chemotherapy: a report from Greece. <i>Palliative Medicine</i> , 2002, 16, 315-321.	1.3	67

#	ARTICLE	IF	CITATIONS
37	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	1.4	67
38	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1-LBA1.	0.8	64
39	Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2004, 15, 1517-1526.	0.6	63
40	Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.3	62
41	Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. <i>Annals of Oncology</i> , 2005, 16, 869-877.	0.6	62
42	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 131-143.	1.1	61
43	Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. <i>Pharmacogenomics Journal</i> , 2012, 12, 468-475.	0.9	60
44	Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2002, 13, 1737-1742.	0.6	59
45	Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas. <i>Oncology</i> , 2009, 77, 1-11.	0.9	59
46	The informational needs, satisfaction with communication, and psychological status of primary caregivers of cancer patients receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2001, 9, 591-596.	1.0	56
47	Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>British Journal of Cancer</i> , 2008, 99, 1775-1785.	2.9	56
48	Brain metastasis in renal cell cancer responding to sunitinib. <i>Anticancer Research</i> , 2007, 27, 4255-7.	0.5	55
49	Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?. <i>Supportive Care in Cancer</i> , 2005, 13, 647-651.	1.0	54
50	ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 127-141.	1.0	52
51	Physicians' brain drain in Greece: A perspective on the reasons why and how to address it. <i>Health Policy</i> , 2014, 117, 210-215.	1.4	51
52	bcl-2/bax Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients With Rectal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2001, 9, 329-334.	0.6	48
53	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 609-619.	1.1	48
54	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 791-803.	1.1	46

#	ARTICLE	IF	CITATIONS
55	The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. <i>Melanoma Research</i> , 2004, 14, 289-294.	0.6	45
56	Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 950-957.	0.6	45
57	Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. <i>European Journal of Cancer Care</i> , 2007, 16, 231-237.	0.7	45
58	Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2008, 19, 115-122.	0.6	45
59	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. <i>Annals of Oncology</i> , 2008, 19, 853-860.	0.6	45
60	Autophagy: novel action of panitumumab in colon cancer. <i>Anticancer Research</i> , 2009, 29, 5077-82.	0.5	45
61	Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. <i>International Journal of Cancer</i> , 2002, 102, 86-90.	2.3	44
62	Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. <i>BMC Cancer</i> , 2011, 11, 314.	1.1	44
63	A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2010, 8, 3.	2.3	42
64	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2011, 9, 10.	2.3	41
65	Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. <i>Gynecologic Oncology</i> , 2004, 95, 695-700.	0.6	39
66	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 701-706.e1.	0.6	39
67	POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?. <i>Anticancer Research</i> , 2008, 28, 1221-7.	0.5	39
68	Impact of Cancer on Primary Caregivers of Patients Receiving Radiation Therapy. <i>Acta Oncologica</i> , 2001, 40, 766-771.	0.8	38
69	The Potential Role of TGF $\beta$ 1, TGF $\beta$ 2 and TGF $\beta$ 3 Protein Expression in Colorectal Carcinomas. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 201-208.	1.0	38
70	Effect of Recombinant Human Erythropoietin on Quality of Life in Cancer Patients Receiving Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2003, 25, 512-518.	0.6	37
71	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 237-247.	2.0	37
72	Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2009, 76, 275-285.	0.9	37

#	ARTICLE	IF	CITATIONS
73	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
74	Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. <i>Journal of Neuro-Oncology</i> , 2012, 106, 23-31.	1.4	37
75	Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. <i>Histopathology</i> , 2006, 49, 582-593.	1.6	36
76	Enhancement of TGF- $\beta$ 2 Signaling Responses by the E3 Ubiquitin Ligase Arkadia Provides Tumor Suppression in Colorectal Cancer. <i>Cancer Research</i> , 2011, 71, 6438-6449.	0.4	36
77	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CLIPINOM study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	1.4	36
78	Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 523-530.	1.6	36
79	LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 727-737.	1.4	36
80	Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Cancer Investigation</i> , 2004, 22, 655-662.	0.6	35
81	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 1-9.	1.1	35
82	Identification of novel human receptor activator of nuclear factor- $\kappa$ B isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. <i>Breast Cancer Research</i> , 2012, 14, R112.	2.2	35
83	EGFR, HER2 and COX2 levels in colorectal cancer. <i>Histopathology</i> , 2008, 53, 698-706.	1.6	34
84	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	1.4	34
85	The Fire Within: NF- $\kappa$ B Involvement in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 4025-4036.	0.4	34
86	Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2001, 12, 1417-1422.	0.6	33
87	Epothilone-Induced Peripheral Neuropathy: A Review of Current Knowledge. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 931-940.	0.6	33
88	Antiproliferative effect of exemestane in lung cancer cells. <i>Molecular Cancer</i> , 2009, 8, 109.	7.9	32
89	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
90	A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 103-110.	0.4	31

#	ARTICLE	IF	CITATIONS
91	Integrin beta $\alpha$ 3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?. European Journal of Neurology, 2010, 17, 963-968.	1.7	31
92	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cellular Oncology (Dordrecht), 2011, 34, 381-391.	2.1	31
93	A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of Oncology, 1997, 8, 1213-1220.	0.6	30
94	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: <scp><i>post hoc</i></scp> analysis of a prospective study. European Journal of Neurology, 2013, 20, 788-794.	1.7	30
95	Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem. Journal of Breast Cancer, 2015, 18, 207.	0.8	30
96	Lapatinib-induced hepatitis: A case report. World Journal of Gastroenterology, 2011, 17, 2349.	1.4	30
97	Hepatocellular carcinoma metastasis in the pituitary gland: case report and review of the literature. Journal of Neuro-Oncology, 2003, 63, 173-177.	1.4	29
98	<i>KRAS</i>,<i>NRAS</i>and<i>BRAF</i>mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open, 2014, 4, e004652.	0.8	29
99	Association of FOXP3 expression with non-small cell lung cancer. Anticancer Research, 2011, 31, 1677-83.	0.5	29
100	Paclitaxel plus carboplatin-induced peripheral neuropathy. Journal of Neurology, 2005, 252, 1459-1464.	1.8	28
101	HER-3 in colorectal tumorigenesis: From mRNA levels through protein status to clinicopathologic relationships. European Journal of Cancer, 2007, 43, 2602-2611.	1.3	28
102	Molecularly Targeted Therapies for Malignant Gliomas. Molecular Medicine, 2009, 15, 115-122.	1.9	28
103	Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncologica, 2008, 47, 1148-1155.	0.8	27
104	Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histology and Histopathology, 2010, 25, 299-307.	0.5	27
105	Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies. Current Medicinal Chemistry, 2009, 16, 3797-3804.	1.2	26
106	Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemotherapy and Pharmacology, 2008, 62, 277-284.	1.1	25
107	Estrogen receptor $\beta$ , AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?. International Journal of Colorectal Disease, 2009, 24, 613-622.	1.0	25
108	Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Critical Reviews in Oncology/Hematology, 2009, 69, 199-210.	2.0	25

#	ARTICLE	IF	CITATIONS
109	Preliminary Results of the Use of Re-186-HEDP for Palliation of Pain in Patients With Metastatic Bone Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 83-88.	0.6	25
110	Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. <i>Cellular Oncology</i> , 2009, 31, 235-47.	1.9	25
111	Phase II study of docetaxel+vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. <i>Annals of Oncology</i> , 2003, 14, 1094-1099.	0.6	24
112	Radioimmunosintigraphy in Patients with Ovarian Cancer. <i>Acta OncolÃ³gica</i> , 2001, 40, 549-557.	0.8	23
113	Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1990-1997.	1.1	23
114	Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Annals of Oncology</i> , 2009, 20, 1362-1368.	0.6	23
115	An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 554-560.	1.2	23
116	Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	23
117	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	1.0	23
118	Monoclonal Antibodies in the Management of Solid Tumors. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1687-1705.	1.0	22
119	Impact of providing booklets about chemotherapy to newly presenting patients with cancer: a randomized controlled trial. <i>Annals of Oncology</i> , 2006, 17, 515-520.	0.6	22
120	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-Î³B activation and EGFR signaling. <i>Oncogene</i> , 2018, 37, 5101-5114.	2.6	22
121	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	1.9	22
122	Title is missing!. <i>Applied Immunohistochemistry &amp; Molecular Morphology</i> , 2001, 9, 329-334.	2.0	21
123	Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 166-174.	1.4	21
124	Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Annals of Oncology</i> , 2005, 16, 1116-1122.	0.6	20
125	Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2006, 17, 1560-1567.	0.6	20
126	A phase II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane+platinum-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 51-59.	1.1	20



#	ARTICLE	IF	CITATIONS
127	Medical students' views of undergraduate oncology education: A comparative study. <i>Education for Health: Change in Learning and Practice</i> , 2006, 19, 61-70.	0.1	20
128	Altered expression of NFY-C and RORA in colorectal adenocarcinomas. <i>Acta Histochemica</i> , 2012, 114, 553-561.	0.9	20
129	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
130	Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 853-858.	1.9	20
131	Capecitabine-induced hypertriglyceridemia: a report of two cases. <i>Anticancer Research</i> , 2006, 26, 2249-51.	0.5	20
132	Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. <i>In Vivo</i> , 2014, 28, 315-26.	0.6	20
133	Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Cancer</i> , 2008, 44, 2169-2177.	1.3	19
134	Dual targeting of EGFR and HER-2 in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 973-981.	1.1	19
135	NSCLC and the alternative pathway of NF- $\kappa$ B: uncovering an unknown relation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 515-523.	1.4	19
136	Multiple primary malignancies: a report of two cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2014, 26, 215-8.	0.7	19
137	TGF-beta repressors SnoN and Ski are implicated in human colorectal carcinogenesis. <i>Cellular Oncology</i> , 2009, 31, 41-51.	1.9	19
138	Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 1999, 10, 475-478.	0.6	18
139	The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently. <i>BioMed Research International</i> , 2013, 2013, 1-14.	0.9	18
140	Expression patterns of SDF1/CXCR4 in human invasive breast carcinoma and adjacent normal stroma: Correlation with tumor clinicopathological parameters and patient survival. <i>Pathology Research and Practice</i> , 2014, 210, 662-667.	1.0	18
141	Focal Adhesion Proteins $\beta$ - and $\beta$ 2-Parvin are Overexpressed in Human Colorectal Cancer and Correlate with Tumor Progression. <i>Cancer Investigation</i> , 2015, 33, 387-397.	0.6	18
142	Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach. <i>Human Genomics</i> , 2015, 9, 12.	1.4	18
143	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. <i>Anticancer Research</i> , 2005, 25, 3103-8.	0.5	18
144	Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. <i>In Vivo</i> , 2007, 21, 113-8.	0.6	18

#	ARTICLE	IF	CITATIONS
145	ILK overexpression in human hepatocellular carcinoma and liver cirrhosis correlates with activation of Akt. <i>Oncology Reports</i> , 2008, 20, 1337-44.	1.2	18
146	An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 265-275.	2.0	17
147	Liability of the Voltage-Gated Sodium Channel Gene <i>SCN2A</i> ; R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy. <i>Oncology</i> , 2009, 77, 254-256.	0.9	17
148	Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2010, 10, 230-237.	1.1	17
149	The Survivin $\Delta 31$ Snp in Human Colorectal Cancer Correlates with Survivin Splice Variant Expression and Improved Overall Survival. <i>Analytical Cellular Pathology</i> , 2010, 33, 177-189.	0.7	17
150	Bevacizumab in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 75-82.	3.4	17
151	Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges. <i>Current Medicinal Chemistry</i> , 2011, 18, 1599-1612.	1.2	17
152	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 1991-1995.	1.0	17
153	Differentially Methylated Ultra-Conserved Regions Uc160 and Uc283 in Adenomas and Adenocarcinomas Are Associated with Overall Survival of Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 895.	1.7	17
154	Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. <i>Cancer Letters</i> , 2006, 244, 34-41.	3.2	16
155	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. <i>Oncology</i> , 2007, 72, 388-396.	0.9	16
156	VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5791.	1.8	16
157	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16
158	Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors. <i>Molecular Medicine</i> , 2009, 15, 183-191.	1.9	15
159	Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. <i>Human Genomics</i> , 2013, 7, 14.	1.4	15
160	Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. <i>Journal of Biomedical Science</i> , 2015, 22, 98.	2.6	15
161	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 773-779.	0.6	14
162	Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 161-167.	1.1	14

#	ARTICLE	IF	CITATIONS
163	Prion protein expression and the M129V polymorphism of the <i>PRNP</i> gene in patients with colorectal cancer. <i>Molecular Carcinogenesis</i> , 2010, 49, 693-699.	1.3	14
164	RANK and EGFR in invasive breast carcinoma. <i>Cancer Genetics</i> , 2017, 216-217, 61-66.	0.2	14
165	Expression Of Intracellular Components of the NF- $\kappa$ B Alternative Pathway (NF- $\kappa$ B2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients. <i>Scientific Reports</i> , 2019, 9, 14299.	1.6	14
166	The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. <i>Anticancer Research</i> , 2010, 30, 4987-92.	0.5	14
167	The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study. <i>European Journal of Neurology</i> , 2005, 12, 858-861.	1.7	13
168	Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008, 110, 87-92.	0.6	13
169	Religiosity and its relation to quality of life in Christian Orthodox cancer patients undergoing chemotherapy. <i>Psycho-Oncology</i> , 2009, 18, 284-289.	1.0	13
170	Prognostic Significance of Dicer Cellular Levels in Soft Tissue Sarcomas. <i>Cancer Investigation</i> , 2012, 30, 172-179.	0.6	13
171	Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2015, 89, 311-319.	0.9	13
172	Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>International Journal of Neuroscience</i> , 2022, 132, 643-648.	0.8	13
173	Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. <i>Journal of Molecular Histology</i> , 2020, 51, 385-400.	1.0	13
174	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. <i>Analytical Cellular Pathology</i> , 2010, 33, 177-89.	0.7	13
175	A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2002, 98, 141-147.	2.3	12
176	Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 207-212.	1.1	12
177	Estrogen signaling in colorectal carcinoma microenvironment: expression of ER $\alpha$ , AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 389-399.	1.4	12
178	Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 189-193.	0.8	12
179	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Oncology Reports</i> , 2011, 27, 216-24.	1.2	12
180	Assessment of sexual function in patients with cancer undergoing radiotherapy--a single centre prospective study. <i>Anticancer Research</i> , 2012, 32, 657-64.	0.5	12

#	ARTICLE	IF	CITATIONS
181	Oval cell proliferation in cirrhosis in rats. An experimental study. <i>Hepatology Research</i> , 2007, 37, 755-764.	1.8	11
182	Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with worse prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 41-53.	1.4	11
183	Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions. <i>Current Medicinal Chemistry</i> , 2011, 18, 1584-1598.	1.2	11
184	Vitamin E for preventing chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2011, 19, 725-726.	1.0	11
185	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	1.4	11
186	Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications. <i>Biosensors</i> , 2022, 12, 97.	2.3	11
187	Vinorelbine in Combination with Interleukin-2 as Second-Line Treatment in Patients with Metastatic Melanoma. A Phase II Study of the Hellenic Cooperative Oncology Group. <i>Cancer Investigation</i> , 2004, 22, 832-839.	0.6	10
188	Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. <i>Gastric Cancer</i> , 2006, 9, 26-31.	2.7	10
189	Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. <i>Acta Oncologica</i> , 2008, 47, 1171-1173.	0.8	10
190	VEGF polymorphisms may be associated with susceptibility to colorectal cancer: A case-control study. <i>Cancer Biomarkers</i> , 2012, 10, 213-217.	0.8	10
191	Alternative splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered capacity to activate NF- $\kappa$ B. <i>Gene</i> , 2013, 525, 124-129.	1.0	10
192	The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines. <i>Pharmaceutical Biology</i> , 2014, 52, 444-452.	1.3	10
193	Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LT $\beta$ R is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 741.	1.0	10
194	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , 2019, 39, 1403-1409.	0.5	10
195	Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas. <i>Oncotarget</i> , 2018, 9, 21411-21428.	0.8	10
196	A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 23-30.	0.6	9
197	Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report. <i>Journal of Neuro-Oncology</i> , 2011, 101, 509-511.	1.4	9
198	Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Annals of Oncology</i> , 2011, 22, 827-834.	0.6	9

#	ARTICLE	IF	CITATIONS
199	Angiogenesis as a therapeutic target in breast cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1230-1238.	1.1	9
200	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	0.9	9
201	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 1807-1814.	1.0	9
202	Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2008, 28, 2913-20.	0.5	9
203	Monoclonal Antibodies. <i>Drugs</i> , 1989, 38, 645-657.	4.9	8
204	Effect of epoetin alfa therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. <i>European Journal of Cancer Care</i> , 2008, 17, 535-41.	0.7	8
205	Large Cell Neuroendocrine Carcinoma of the Lung Metastatic to the Shoulder Joint, Causing Suprascapular Nerve Palsy. <i>Journal of Pain and Symptom Management</i> , 2011, 42, e1-e3.	0.6	8
206	Regioselective chemical and rapid enzymatic synthesis of a novel redox active Antiproliferative molecular hybrid. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 47-57.	2.6	8
207	NF- $\kappa$ B2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival. <i>Scientific Reports</i> , 2018, 8, 5259.	1.6	8
208	PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. <i>Cancers</i> , 2020, 12, 1257.	1.7	8
209	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020, 123, 355-361.	2.9	8
210	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 178-183.	1.4	8
211	Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells. <i>Cancer Genomics and Proteomics</i> , 2011, 8, 33-8.	1.0	8
212	A Phase II Study with CPT-11 Plus Leucovorin and Bolus IV 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma. <i>Cancer Investigation</i> , 2003, 21, 855-862.	0.6	7
213	Adriamycin and Cis-Platinum as First-Line Treatment in Unresectable Locally Advanced or Metastatic Adult Soft-Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 307-311.	0.6	7
214	Positive association between two polymorphic sites (+134 insA/delA and G198T) of the endothelin-1 gene and chronic obstructive pulmonary disease. A case-control study. <i>Respiratory Medicine</i> , 2010, 104, 114-120.	1.3	7
215	The Impact of Anti-tumor Agents on ER-Positive MCF-7 and HER2-Positive SKBR-3 Breast Cancer Cells Biomechanics. <i>Annals of Biomedical Engineering</i> , 2019, 47, 1711-1724.	1.3	7
216	Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3753.	1.8	7

#	ARTICLE	IF	CITATIONS
217	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	2.0	7
218	Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study. <i>Anticancer Research</i> , 2003, 23, 1687-91.	0.5	7
219	Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 521-528.	1.1	6
220	The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. <i>Urology</i> , 2005, 66, 382-385.	0.5	6
221	Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008, 111, 27-34.	0.6	6
222	Clonal rearrangement of the Tâ€cell receptor Î³ gene associated with a bizarre lymphoproliferative syndrome. <i>European Journal of Haematology</i> , 1988, 41, 289-294.	1.1	6
223	Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. <i>Pharmacogenomics Journal</i> , 2014, 14, 248-255.	0.9	6
224	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1289-1301.	1.1	6
225	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4885-4893.	1.0	6
226	Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 690-697.	1.4	6
227	Iris Metastasis in a Patient With Small Cell Lung Cancer: A Case Report. <i>Iranian Red Crescent Medical Journal</i> , 2016, 18, e21522.	0.5	6
228	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Anti-Cancer Drugs</i> , 2004, 15, 479-487.	0.7	5
229	Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatinâ€induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 43-48.	1.4	5
230	Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP85-99) epitope: Towards selective immunosuppression. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 621-631.	2.6	5
231	The role of monoclonal antibodies in tumour diagnosis. <i>Cancer Treatment Reviews</i> , 1986, 13, 243-252.	3.4	4
232	Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer. <i>Cancer Investigation</i> , 2001, 19, 137-144.	0.6	4
233	Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 591-596.	0.6	4
234	Cardiovascular effects of treatment with taxanes. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 319-324.	0.6	4

#	ARTICLE	IF	CITATIONS
235	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. <i>Future Oncology</i> , 2022, 18, 2361-2371.	1.1	4
236	Mitomycin C and Vinblastine in Anthracycline-resistant Metastatic Breast Cancer: A Phase II Study. <i>Tumori</i> , 2001, 87, 394-397.	0.6	3
237	Absence of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism: case report. <i>Annals of Oncology</i> , 2003, 14, 1690-1691.	0.6	3
238	A Case of Chondrosarcoma Developing in a Recurrent Retroperitoneal Mass after Chemotherapy for Testicular Germ Cell Tumor. <i>Urologia Internationalis</i> , 2006, 77, 86-88.	0.6	3
239	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer. <i>Medical Oncology</i> , 2007, 24, 301-307.	1.2	3
240	Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. <i>Current Molecular Pharmacology</i> , 2015, 7, 33-43.	0.7	3
241	Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1092, 515-523.	1.2	3
242	Radiotherapy and Renal Cell Carcinoma: A Continuing Saga. <i>In Vivo</i> , 2021, 35, 1365-1377.	0.6	3
243	Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain. <i>The Journal of Supportive Oncology</i> , 2006, 4, 168.	2.3	3
244	Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. <i>Anticancer Research</i> , 2010, 30, 4325-33.	0.5	3
245	Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients With Breast Cancer and One to Nine Infiltrated Nodes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 57-67.	0.6	2
246	Mitogen-activated protein kinases in gliomas and correlation with patients' prognosis. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 226-233.	1.0	2
247	Seasonal variability in the incidence of carcinomatous meningitis. <i>Journal of Neurosurgery</i> , 2015, 122, 543-546.	0.9	2
248	Three Regioselectively Acylated Flavonoid Aglycone Derivatives in Equimolar Yield at One Blow. <i>ChemistrySelect</i> , 2018, 3, 5207-5211.	0.7	2
249	NF- $\kappa$ B2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development. <i>Translational Oncology</i> , 2021, 14, 100912.	1.7	2
250	Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15601-e15601.	0.8	2
251	The clinical significance of NF- $\kappa$ B2, RelB, NIK, and BCL3 expression in NSCLC.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18511-e18511.	0.8	2
252	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.3	2

#	ARTICLE	IF	CITATIONS
253	A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). <i>Sarcoma</i> , 2004, 8, 129-133.	0.7	1
254	Myelotoxicity in Cancer Patients Treated with Chemotherapy: Negative or Positive Prognostic Factor?. <i>Clinical Cancer Research</i> , 2008, 14, 7579-7579.	3.2	1
255	Promises and hurdles of undergraduate medical development in Greece. <i>Advances in Medical Education and Practice</i> , 2011, 2, 201.	0.7	1
256	Ulcerative colitis six years after colon cancer: only a coincidence?. <i>International Medical Case Reports Journal</i> , 2014, 7, 85.	0.3	1
257	In Reply. <i>Oncologist</i> , 2020, 25, e2023.	1.9	1
258	Genetic Variations of CD40 and LT $\beta$ R Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 721577.	1.3	1
259	PIOS ratio: predicting the best response of non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21507-e21507.	0.8	1
260	TGF- $\beta$ 2 Repressors SnoN and Ski Are Implicated in Human Colorectal Carcinogenesis. <i>Analytical Cellular Pathology</i> , 2009, 31, 41-51.	0.7	1
261	A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). <i>Sarcoma</i> , 2004, 8, 129-33.	0.7	1
262	Prospective assessment of psychopathological symptoms and their relation to demographic factors in primary caregivers of cancer patients throughout chemotherapy. <i>Supportive Care in Cancer</i> , 2021, , 1.	1.0	1
263	Hepatocellular carcinoma in hepatectomized patients: biologic and therapeutic implications. <i>Anticancer Research</i> , 2005, 25, 3067-73.	0.5	1
264	Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine. <i>Current Signal Transduction Therapy</i> , 2009, 4, 6-21.	0.3	0
265	Lack of association of the M129V polymorphism of the PRNP gene with pseudoexfoliation syndrome. <i>Clinical Ophthalmology</i> , 2016, 10, 731.	0.9	0
266	Identification of a seasonal pattern to brain metastases. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 609.	1.0	0
267	Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports. <i>Molecular and Clinical Oncology</i> , 2016, 5, 803-806.	0.4	0
268	Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	0
269	Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21164-e21164.	0.8	0
270	RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs). <i>Genes</i> , 2021, 12, 1686.	1.0	0



#	ARTICLE	IF	CITATIONS
271	Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.. Journal of Clinical Oncology, 2012, 30, 9090-9090.	0.8	0
272	BCL3 and NSCLC: Are they related?. Journal of Clinical Oncology, 2013, 31, e18507-e18507.	0.8	0
273	Evaluation of NF- $\kappa$ B2 polymorphisms rs7897947, rs11574852 and rs12769316 in NSCLC: A case-control study.. Journal of Clinical Oncology, 2014, 32, e22044-e22044.	0.8	0
274	Patterns of practice in the management of advanced urothelial cancer (UC) in Greece: A retrospective analysis by the hellenic GU Cancer Group (HGUCG).. Journal of Clinical Oncology, 2014, 32, e15514-e15514.	0.8	0
275	RANK/EGFR interplay in breast cancer.. Journal of Clinical Oncology, 2016, 34, e13011-e13011.	0.8	0
276	NF- $\kappa$ B2 SNPs, rs7897947, and rs12769316 and survival outcome of NSCLC patients.. Journal of Clinical Oncology, 2016, 34, e13012-e13012.	0.8	0
277	Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their diagnostic and prognostic value.. Journal of Clinical Oncology, 2017, 35, e15130-e15130.	0.8	0
278	The alternative NF- $\kappa$ B pathway in colorectal cancer: From genetic polymorphisms through mRNA to protein levels.. Journal of Clinical Oncology, 2018, 36, e15619-e15619.	0.8	0
279	<i>VEGF-A</i> polymorphisms affect the pharmacologic effect of bevacizumab on VEGF-A levels in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e15505-e15505.	0.8	0
280	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 2022, 14, 1168.	1.7	0
281	Prognostic value of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with combination of immunotherapy with chemotherapy: Preliminary results from a European retrospective study.. Journal of Clinical Oncology, 2022, 40, e21096-e21096.	0.8	0